Table 1.
Patient demographics and clinical characteristics
| Characteristic | All patients (N = 32) |
|---|---|
| Sex, M/F (%) | 14/18 (44/56) |
| Age at MM diagnosis, median (range), y | 59 (46-77) |
| Age at ALL/BALLP diagnosis, median (range), y | 65 (50-86) |
| Time from MM to ALL/BALLLP, median (range), y | 5.5 (0.6-11.7) |
| Length of lenalidomide exposure, median (range), mo | 41.8 (1.8-114.1) |
| MM characteristics, n (%) | |
| IgG heavy chain | 19 (59) |
| IgA heavy chain | 8 (25) |
| Unknown heavy chain | 3 (9) |
| Light chain only MM | 2 (6) |
| κ light chain | 19 (59) |
| λ light chain | 12 (38) |
| Unknown light chain | 1 (3) |
| MM presentation, n (%) | |
| Hypercalcemia | 2 (6) |
| Renal insufficiency | 5 (16) |
| Anemia | 9 (2) |
| Bony lesions | 25 (7) |
| CRAB criteria status unknown | 3 (9) |
| Leptomeningeal disease | 1 (3) |
| ALL/BALLLP lineage and presentation, n (%) | |
| T-cell | 0 |
| B-cell | 32 (100) |
| Overt B-ALL at diagnosis | 29 (91) |
| BALLLP at diagnosis | 3 (9) |
| BCR::ABL-positive | 1 (3) |
| BCR::ABL-negative | 31 (91) |
| CD10 expression | 29 (91) |
| CD20 expression | 18 (56) |
| Low hypodiploidy∗ | 8 (31)† |
| 11q23 rearrangement‡ | 2 (8)† |
F, female; M, male.
∗
Includes patients with low hypodiploid features by traditional karyotyping (n = 5) or by FISH (n = 3).
†
Because low disease burden and/or lack of comprehensive cytogenetic data for 6 patients in the series, total evaluable patients here are considered as 26 rather than 32.
‡
Refer to Discussion in the manuscript; possible but not definite in 1 of 2 patients.